Teva

HERZUMA

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / HERZUMA – Q5113

Manufacturer:

Teva

Name:

HERZUMA

HCPCS Code Descriptor:

Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg

Category:

Q Code

HCPCS:

Q5113

NDC(s):

63459-0305-47, 63459-0303-43

Primary Type:

Oncology Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

HERZUMA is an Oncology Biosimilar drug manufactured by Teva and administered via the Intravenous route of administration. The Q Code: Q5113 is aligned to the drug HERZUMA.

Herzuma (trastuzumab) is used to treat specific types of breast and stomach cancers by targeting the HER2 protein in cancer cells. Herzuma can be used in combination with other cancer medications. This medication is manufactured by Cephalon and is biosimilar to the medication Herceptin (J9356). Herzuma has been aligned to the Q Code Q5113 since July 2019. Patient assistance programs for this medication can be found through Truxima.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/19

HCPCS Effective Date:

7/1/19

HCPCS Short Description:

Inj herzuma 10 mg

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.truximahcp.com/support-resources

HERZUMA - Q5113